Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2018

Kitajima Shunsuke, Barbie David A

Abstract excerpt

Although mutation of NF1 has been described in non-small cell lung cancer (NSCLC), co-mutation with RASA1, another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. RASA1/NF1-mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients. Clin Cancer Res; 24(6); 1243-5. ©2018 AACRSee related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to p120 GTPase Activating Protein

Share to Protein Kinase Inhibitors

Share to Smoking

Source

Open in PubMed Open full text

Identifiers

PMID: 29343556
DOI: 10.1158/1078-0432.CCR-17-3597
PMCID: PMC5856629

Genes

RASA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?PMID 29343556Read ↗

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.Semantic proximity Read ↗

Clinical and Molecular Characteristics of NF1 -Mutant Lung CancerSemantic proximity Read ↗

Advancement in research and therapy of NF1 mutant malignant tumorsSemantic proximity Read ↗

Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.Semantic proximity Read ↗

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.Semantic proximity Read ↗

Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.Semantic proximity Read ↗

MicroRNA‑103a‑3p potentiates chemoresistance to cisplatin in non‑small cell lung carcinoma by targeting neurofibromatosis 1Semantic proximity Read ↗

Paths of resistance to EGFR inhibitors: is NF enough?Semantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Semantic proximity Read ↗

Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTsSemantic proximity Read ↗

RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung AdenocarcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.